AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30098961 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 108
Study 26556736 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5442 (5, 7.5, 10, or 15 mg daily)
Number of subjects: 526
Study 26556736 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5442 (10 mg)
Number of subjects: 526
Study 26556736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526
Study 26556736 — intervention group
Group type: COMPARATOR
Intervention: ALN 70 mg weekly
Number of subjects: 526
Study 25662545 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine (1500 mg) and Chondroitin (1200 mg) combination
Number of subjects: 31
Study 25662545 — intervention group
Group type: COMPARATOR
Intervention: Tramadol HCl (50 mg, twice daily)
Number of subjects: 31
Study 22994907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical OMT
Number of subjects: 19
Study 22994907 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 19
Study 22994907 — intervention group
Group type: COMPARATOR
Intervention: Time control
Number of subjects: 19
Study 20669577 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle warming therapy
Number of subjects: 120
Study 20669577 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture treatment
Number of subjects: 120
Study 20669577 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture treatment
Number of subjects: 120
Study 18675854 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 17
Study 18675854 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 17
Study 18675854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18675854 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 and 10 microg)
Number of subjects: 17
Study 18675854 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 17
Study 16639670 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 281
Study 16639670 — intervention group
Group type: EXPERIMENTAL
Intervention: POAG
Number of subjects: 281
Study 16639670 — intervention group
Group type: EXPERIMENTAL
Intervention: PSXG
Number of subjects: 281
Study 16639670 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG
Number of subjects: 281
Study 16639670 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 0 GONHA
Number of subjects: 281
Study 16639670 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages 1 to 4 GONHA
Number of subjects: 281
Study 16639670 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 1 GONHA
Number of subjects: 281
Study 16639670 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 GONHA
Number of subjects: 281
Study 16639670 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages 3 and 4 GONHA
Number of subjects: 281
Study 14616152 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RB) 20 mg/d in the evening (p.m.)
Number of subjects: 20
Study 14616152 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RB) 20 mg/d in the morning (a.m.)
Number of subjects: 20
Study 11062356 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate
Number of subjects: 46
Study 11062356 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 500 mg calcium supplement
Number of subjects: 46
Study 8629588 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg/day orally)
Number of subjects: 10
Study 8629588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8629588 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (normal volunteers)
Number of subjects: 10
Study 1599888 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg meperidine
Number of subjects: 100
Study 1599888 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg bupivacaine
Number of subjects: 100
Study 1599888 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg meperidine plus 12.5 mg bupivacaine
Number of subjects: 100
Study 1599888 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg bupivacaine
Number of subjects: 100
Study 1599888 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg bupivacaine
Number of subjects: 100
Study 1599888 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 100
Study 1599888 — intervention group
Group type: COMPARATOR
Intervention: Neonatal neurologic and adaptive capacity scores
Number of subjects: 100
Study 4054206 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 6
Study 29792370 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg plus standard of care (SoC)
Number of subjects: 60
Study 29792370 — intervention group
Group type: COMPARATOR
Intervention: placebo plus standard of care (SoC)
Number of subjects: 60
Study 29979143 — intervention group
Group type: EXPERIMENTAL
Intervention: SMARTgirl HIV prevention programme for ≥ 6 months
Number of subjects: 596
Study 29979143 — intervention group
Group type: COMPARATOR
Intervention: No living children
Number of subjects: 596
Study 29979143 — intervention group
Group type: COMPARATOR
Intervention: Recent food insecurity
Number of subjects: 596
Study 27338954 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 144
Study 27338954 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved fitness
Number of subjects: 144
Study 27338954 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dietary sodium
Number of subjects: 144
Study 27338954 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to DASH diet
Number of subjects: 144
Study 24552524 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression-only CPR training (45-minute program)
Number of subjects: 146
Study 24552524 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR training (180-minute program)
Number of subjects: 146
Study 22440488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg, 3 times daily, starting 6 hours before ascent
Number of subjects: 86
Study 22440488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 19341510 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (flexible dosages up to 200 mg/d)
Number of subjects: 368
Study 19341510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy (one individual session and nine group sessions per 90 min)
Number of subjects: 368
Study 19341510 — intervention group
Group type: COMPARATOR
Intervention: Guided self-help group (control condition)
Number of subjects: 368
Study 19341510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' choice arm (sertraline or cognitive-behavioural group therapy)
Number of subjects: 368
Study 17493418 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d)
Number of subjects: 1632
Study 17493418 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 1632
Study 17493418 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (20 mg/d)
Number of subjects: 1632
Study 17493418 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1632
Study 16767609 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Load (1.1 kg weight on each ankle)
Number of subjects: 85
Study 16767609 — intervention group
Group type: COMPARATOR
Intervention: No Load (no external load)
Number of subjects: 85
Study 14558586 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐Tip intraosseous technique
Number of subjects: 41
Study 14558586 — intervention group
Group type: COMPARATOR
Intervention: Stabident intraosseous technique
Number of subjects: 41
Study 11154053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheng-ji-san (SJS) treatment combined with routine medical care
Number of subjects: 32
Study 11154053 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care
Number of subjects: 32
Study 9238897 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF dentifrice containing 5.0% pyrophosphate (Crest Tartar Control)
Number of subjects: 346
Study 9238897 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF dentifrice containing 5.0% pyrophosphate plus 0.28% triclosan (antimicrobial)
Number of subjects: 346
Study 9238897 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (NaF only, Crest)
Number of subjects: 346
Study 1630773 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonal-progressive multifocal IOL
Number of subjects: 62
Study 1630773 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 62
Study 6149535 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (1.5 mg/kg orally)
Number of subjects: 8
Study 6149535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30095981 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 30 mg/kg intravenously
Number of subjects: 67
Study 30095981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 27816115 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Chloride levels measured at randomization and during hospitalization
Number of subjects: 358
Study 27816115 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloride change
Number of subjects: 358
Study 26978497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific cytoprotective therapy (cytoflavin)
Number of subjects: 266
Study 26978497 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 266
Study 24337064 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment for 6 months
Number of subjects: 62
Study 24337064 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 62
Study 21782166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg/day for 5 days
Number of subjects: 82
Study 21782166 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (R) 100 mg/day for 5 days
Number of subjects: 82
Study 19103217 — intervention group
Group type: EXPERIMENTAL
Intervention: Different spatial patterns (square, horizontal line, vertical line, T-shape, random shape, no local grouping)
Number of subjects: 0
Study 19103217 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-polarity information (interaction of the On and Off pathways)
Number of subjects: 0
Study 19103217 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-frame motion sequence
Number of subjects: 0
Study 19103217 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric conditions
Number of subjects: 0
Study 17570206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy (clarithromycin 750 mg/day, rifabutin 450 mg/day, clofazimine 50 mg/day)
Number of subjects: 213
Study 17570206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 17570206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy
Number of subjects: 213
Study 15389195 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative tumor curettage
Number of subjects: 0
Study 15389195 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11222109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethidium-binding assay of DNA damage
Number of subjects: 20
Study 11222109 — intervention group
Group type: COMPARATOR
Intervention: Thiobarbituric acid test
Number of subjects: 20
Study 11222109 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalytic iron index
Number of subjects: 20
Study 9356530 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene alone
Number of subjects: 9
Study 9356530 — intervention group
Group type: EXPERIMENTAL
Intervention: Canthaxanthin alone
Number of subjects: 9
Study 9356530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dose of beta-carotene and canthaxanthin
Number of subjects: 9
Study 9356530 — intervention group
Group type: COMPARATOR
Intervention: Canthaxanthin
Number of subjects: 9
Study 7524457 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aprotinin (50 mL; 70 mg)
Number of subjects: 100
Study 3036335 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs and drug combinations for recurrent Wilms' tumor
Number of subjects: 0
Study 3036335 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for localized embryonal rhabdomyosarcoma
Number of subjects: 0
Study 3036335 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for tumors of the prostate, bladder neck, or trigone
Number of subjects: 0
Study 3036335 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-containing combination chemotherapy regimens for advanced yolk sac tumor
Number of subjects: 0
Study 3036335 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug combinations in locally advanced tumors
Number of subjects: 0
Study 3036335 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide-containing combination chemotherapy regimens
Number of subjects: 0
Study 29358433 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment + prescribed fluid intake
Number of subjects: 180
Study 29358433 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment + usual fluid intake
Number of subjects: 180
Study 26708858 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal ligation of ITA
Number of subjects: 184
Study 26708858 — intervention group
Group type: COMPARATOR
Intervention: Terminal branches ligation of ITA
Number of subjects: 184
Study 25906703 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic previsit questionnaire (PVQ) with youth violence (YV) questions
Number of subjects: 183
Study 25906703 — intervention group
Group type: COMPARATOR
Intervention: Control group (PVQ without YV questions)
Number of subjects: 183
Study 22958170 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic alcohol abuse in PS patients
Number of subjects: 0
Study 22958170 — intervention group
Group type: COMPARATOR
Intervention: No history of alcohol abuse in PS patients
Number of subjects: 0
Study 20569152 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference arm
Number of subjects: 0
Study 20569152 — intervention group
Group type: COMPARATOR
Intervention: Randomized arm
Number of subjects: 0
Study 18465724 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 5854
Study 18465724 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5854
Study 16495196 — intervention group
Group type: EXPERIMENTAL
Intervention: MDNP model (multidisciplinary doctor-nurse practitioner)
Number of subjects: 1207
Study 12434259 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/70 kg oral caffeine t.i.d. (caffeine maintenance)
Number of subjects: 9
Study 12434259 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d. (control)
Number of subjects: 9
Study 12434259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicotine (1.0 and 2.0 mg/70 kg)
Number of subjects: 9
Study 12434259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (200 and 400 mg/70 kg)
Number of subjects: 9
Study 10845019 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography
Number of subjects: 10
Study 10845019 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein angiography
Number of subjects: 10
Study 9085325 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 0
Study 9085325 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 0
Study 8473463 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 23
Study 8473463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 23
Study 8473463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 23
Study 3513529 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (1 mg/day, adjustable to max 3 mg/day)
Number of subjects: 249
Study 3513529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 3513529 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 249
Study 30388105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue seroprevalence levels
Number of subjects: 0
Study 30388105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue force of infection
Number of subjects: 0
Study 30388105 — intervention group
Group type: EXPERIMENTAL
Intervention: Population density
Number of subjects: 0
Study 30388105 — intervention group
Group type: EXPERIMENTAL
Intervention: City administrative status
Number of subjects: 0
Study 28298187 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered transdiagnostic cognitive behavioural therapy (iCBT)
Number of subjects: 90
Study 28298187 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 90
Study 26181090 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning services (counseling, prescription or procedure related to birth control)
Number of subjects: 295
Study 26181090 — intervention group
Group type: COMPARATOR
Intervention: Tiers I‐II contraceptive methods (sterilization and hormonal)
Number of subjects: 295
Study 23246170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic biodance
Number of subjects: 59
Study 23246170 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 59
Study 21215558 — intervention group
Group type: COMPARATOR
Intervention: Upper-limb aerobic exercise training (ULG)
Number of subjects: 104
Study 21215558 — intervention group
Group type: COMPARATOR
Intervention: Lower-limb aerobic exercise training (LLG)
Number of subjects: 104
Study 21215558 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-exercise control group
Number of subjects: 104
Study 18318607 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlocalized amplitude information with phase randomization
Number of subjects: 0
Study 18318607 — intervention group
Group type: COMPARATOR
Intervention: Localized amplitude information (control)
Number of subjects: 0
Study 16413605 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom only intervention
Number of subjects: 1578
Study 16413605 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom plus semester-long school-as-community component
Number of subjects: 1578
Study 16413605 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 1578
Study 12804986 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 mug/g ointment
Number of subjects: 125
Study 12804986 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol 50 mug/g ointment
Number of subjects: 125
Study 10989245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone therapy (group T)
Number of subjects: 50
Study 10989245 — intervention group
Group type: COMPARATOR
Intervention: Continuous conjugated estrogen (CE) 0.625 mg plus medroxyprogesterone acetate (MPA) 2.5 mg (group E)
Number of subjects: 50
Study 8865212 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually programmed AV delay (optimal AV delay)
Number of subjects: 13
Study 8865212 — intervention group
Group type: COMPARATOR
Intervention: Individually programmed AV delay (most unfavorable AV delay)
Number of subjects: 13
Study 8865212 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status questionnaire
Number of subjects: 13
Study 8865212 — intervention group
Group type: EXPERIMENTAL
Intervention: Total judgment score for optimal AV delay
Number of subjects: 13
Study 8865212 — intervention group
Group type: COMPARATOR
Intervention: Total judgment score for most unfavorable AV delay
Number of subjects: 13
Study 1475418 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 40
Study 6533776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole prophylaxis with 8-h dosage interval (500 mg intravenous infusion)
Number of subjects: 48
Study 6533776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole prophylaxis with 12-h dosage interval (500 mg intravenous infusion)
Number of subjects: 48
Study 6533776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole prophylaxis (500 mg intravenous infusion)
Number of subjects: 48
Study 31394276 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV)
Number of subjects: 0
Study 31394276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29941020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention comprising a distance professional training program on shared decision-making and five shared decision-making tools.
Number of subjects: 180
Study 29941020 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate exposure to the intervention
Number of subjects: 180
Study 29941020 — intervention group
Group type: COMPARATOR
Intervention: Delayed exposure to the intervention
Number of subjects: 180
Study 27565938 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab plus docetaxel
Number of subjects: 160
Study 27565938 — intervention group
Group type: COMPARATOR
Intervention: placebo plus docetaxel
Number of subjects: 160
Study 25587312 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g magnesium sulfate in normal saline infused in 20 minutes on days one to three (case group)
Number of subjects: 30
Study 25587312 — intervention group
Group type: COMPARATOR
Intervention: Standard medications and placebo (control group)
Number of subjects: 30
Study 25587312 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g magnesium sulfate in normal saline (case group)
Number of subjects: 30
Study 25587312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (case group)
Number of subjects: 30
Study 22968127 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy combined with a standardized physical therapy program
Number of subjects: 0
Study 22968127 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical therapy program alone
Number of subjects: 0
Study 21210927 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 16) undergoing psychological stress during a college academic final test
Number of subjects: 33
Study 21210927 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 17) not undergoing the test
Number of subjects: 33
Study 17030560 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 h of cycle ergometer exercise at 60% of maximum oxygen uptake
Number of subjects: 15
Study 17030560 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 15